healthcare, medicine & biotechnology
John L. Wallace
John L. Wallace is an Adjunct Professor of Physiology & Pharmacology at the University of Calgary. In 2004, Dr. Wallace founded Antibe Holdings Ltd., a company developing hydrogen sulfide-releasing drugs. In 2010, he founded Antibe Therapeutics Inc., which became a public company, trading on the Toronto Venture Exchange, in June of 2013. Antibe’s lead drug, ATB-346, is in advanced phase 2 clinical trials for treatment of osteoarthritis. Dr. Wallace obtained his BSc and MSc at Queen’s University, his doctorate at the University of Toronto, and his MBA at the University of Birmingham (UK).